ARCUS BIOSCIENCES INC's ticker is RCUS and the CUSIP is 03969F109. A total of 64 filers reported holding ARCUS BIOSCIENCES INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,288,544 | -2.8% | 406,047 | -1.3% | 0.00% | -25.0% |
Q2 2023 | $7,502,112 | 0.0% | 411,300 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $7,502,112 | -9.7% | 411,300 | +2.4% | 0.00% | 0.0% |
Q4 2022 | $8,308,583 | -99.9% | 401,769 | -10.1% | 0.00% | -42.9% |
Q3 2022 | $11,686,561,000 | +2.4% | 446,734 | -0.8% | 0.01% | +16.7% |
Q2 2022 | $11,417,063,000 | +15.3% | 450,555 | +43.6% | 0.01% | +50.0% |
Q1 2022 | $9,904,729,000 | +1.5% | 313,838 | +30.1% | 0.00% | 0.0% |
Q4 2021 | $9,761,808,000 | +573.3% | 241,211 | +480.2% | 0.00% | +300.0% |
Q3 2021 | $1,449,790,000 | +42.6% | 41,577 | +12.3% | 0.00% | – |
Q2 2021 | $1,016,568,000 | +8.4% | 37,020 | +10.9% | 0.00% | – |
Q1 2021 | $937,479,000 | -4.2% | 33,386 | -11.5% | 0.00% | – |
Q4 2020 | $979,082,000 | +150.5% | 37,715 | +65.4% | 0.00% | – |
Q3 2020 | $390,792,000 | -48.7% | 22,800 | -26.0% | 0.00% | – |
Q2 2020 | $762,363,000 | +18.5% | 30,815 | -26.0% | 0.00% | -100.0% |
Q1 2018 | $643,107,000 | – | 41,652 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Invus Financial Advisors, LLC | 1,612,077 | $28,936,782 | 18.14% |
Octagon Capital Advisors LP | 1,968,000 | $35,325,600 | 5.43% |
Decheng Capital Management III (Cayman), LLC | 869,790 | $15,612,731 | 5.21% |
Boxer Capital, LLC | 1,602,200 | $28,759,490 | 1.53% |
SECTORAL ASSET MANAGEMENT INC | 375,456 | $6,739,435 | 1.31% |
DAFNA Capital Management LLC | 222,717 | $3,997,770 | 1.24% |
PFM Health Sciences, LP | 1,405,056 | $25,220,755 | 1.19% |
Ikarian Capital, LLC | 4,000 | $7,180,000 | 0.86% |
Capital Impact Advisors, LLC | 24,280 | $435,826 | 0.73% |
Parkman Healthcare Partners LLC | 205,109 | $3,681,707 | 0.68% |